The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data
Open accessAbstract
Transarterial chemoembolization (TACE) using lipiodol‐based regimens, including the administration of an anticancer‐in‐oil emulsion followed by embolic agents, is widely used in the treatment of hepatocellular carcinoma (HCC). This approach has been supported by meta‐analyses of randomized, controlled trials (RCTs) performed more than a decade ago. We performed a systematic review to understand current efficacy and safety data of lipiodol TACE in treatment of HCC. A search of the literature published between January 1, 1980 and June 30, 2013 was performed using MEDLINE and EMBASE databases. All potentially relevant publications were reviewed and articles were selected based on predefined inclusion and exclusion criteria. Of a total of 1,564 articles reviewed, 101 articles, including a total of 10,108 patients treated with lipiodol TACE, were selected for the efficacy analysis. Objective response rate was 52.5% (95% confidence interval [CI]: 43.6‐61.5). Overall survival (OS) was 70.3% at 1 year, 51.8% at 2 years, 40.4% at 3 years, and 32.4% at 5 years. Median OS was 19.4 months (95% CI: 16.2‐22.6). A total of 217 articles presenting precise description on numbers of adverse events (AEs) were selected for the safety review: In these studies, a total of 21,461 AEs were reported in 15,351 patients. Liver enzyme abnormalities were the most commonly observed AE, followed by the symptoms associated with postembolization syndrome. Overall mortality rate was 0.6% and the most common cause of death was related to acute liver insufficiency. Conclusions: In a systematic literature review, survival figures of HCC patients undergoing lipiodol TACE appear to be in line with those reported in previous RCTs, and no new or unexpected safety concerns were identified. (H epatology 2016;64:106–116)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Lo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Self-citationLammer, J., Malagari, K., Vogl, T., Pilleul, F., Denys, A., Watkinson, A., Pitton, M., Sergent, G., Pfammatter, T., Terraz, S., et al. (2010) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-009-9711-7 · Cited by 1,557
Self-citationDavis, G. L., Alter, M. J., El–Serag, H., Poynard, T., & Jennings, L. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.067 · Cited by 878
Cammà, C., Schepis, F., Orlando, A., Albanese, M., Shahied, L., Trevisani, F., Andreone, P., Craxì, A., & Cottone, M. (2002) · Radiology · doi:10.1148/radiol.2241011262 · Cited by 851
(1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321903 · Cited by 809
Salem, R., Lewandowski, R. J., Kulik, L., Wang, E., Riaz, A., Ryu, R. K., Sato, K. T., Gupta, R., Nikolaidis, P., Miller, F. H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.049 · Cited by 650
on behalf of the PRECISION ITALIA STUDY GROUP, Golfieri, R., Giampalma, E., Renzulli, M., Cioni, R., Bargellini, I., Bartolozzi, C., Breatta, A. D., Gandini, G., Nani, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.199 · Cited by 606
Bruix, J., Llovet, J. M., Castells, A., Montañá, X., Brú, C., Ayuso, M. D. C., Vilana, R., & Rodés, J. (1998) · Hepatology · doi:10.1002/hep.510270617 · Cited by 533
Loco‐regional treatment of hepatocellular carcinoma†
Lencioni, R. (2010) · Hepatology · doi:10.1002/hep.23725 · Cited by 509
Self-citationPelletier, G., Roche, A., Ink, O., Anciaux, M. L., Derhy, S., Rougier, P., Lenoir, C., Attali, P., & Etienne, J.-P. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90110-d · Cited by 417
Pelletier, G., Ducreux, M., Gay, F., Luboinski, M., Hagège, H., Thong, D., Van Steenbergen, W., Buffet, C., Rougier, P., Adler, M., et al. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80187-6 · Cited by 396
Thomas, M. B., Jaffe, D., Choti, M. M., Belghiti, J., Curley, S., Fong, Y., Gores, G., Kerlan, R., Merle, P., O'Neil, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7805 · Cited by 394
Verslype, C., Rosmorduc, O., & Rougier, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds225 · Cited by 365
Kudo, M., Han, G., Finn, R. S., Poon, R. T. P., Blanc, J.-F., Yan, L., Yang, J., Lu, L., Tak, W.-Y., Yu, X., et al. (2014) · Hepatology · doi:10.1002/hep.27290 · Cited by 355
Lin, D.-Y., Liaw, Y.-F., Lee, T.-Y., & Lai, C.-M. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90436-2 · Cited by 294
Chemoembolization of Hepatocellular Carcinoma
Ramsey, D. E., Kernagis, L. Y., Soulen, M. C., & Geschwind, J.-F. H. (2002) · Journal of Vascular and Interventional Radiology · doi:10.1016/s1051-0443(07)61789-8 · Cited by 271
Self-citationTransarterial (chemo)embolisation for unresectable hepatocellular carcinoma
Oliveri, R. S., Wetterslev, J., & Gluud, C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004787.pub2 · Cited by 268
Miyayama, S., Matsui, O., Yamashiro, M., Ryu, Y., Kaito, K., Ozaki, K., Takeda, T., Yoneda, N., Notsumata, K., Toya, D., et al. (2007) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2006.12.004 · Cited by 260
Fong, Z. V., & Tanabe, K. K. (2014) · Cancer · doi:10.1002/cncr.28730 · Cited by 250
Idée, J.-M., & Guiu, B. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.07.003 · Cited by 227
Lencioni, R., Kudo, M., Ye, S. ‐., Bronowicki, J. ‐., Chen, X. ‐., Dagher, L., Furuse, J., Geschwind, J. F., Guevara, L. L., Papandreou, C., et al. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12352 · Cited by 223
Self-citationChemoembolization for intermediate HCC: Is there proof of survival benefit?
Forner, A., Llovet, J. M., & Bruix, J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.017 · Cited by 109
Okusaka, T., Kasugai, H., Shioyama, Y., Tanaka, K., Kudo, M., Saisho, H., Osaki, Y., Sata, M., Fujiyama, S., Kumada, T., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.09.004 · Cited by 100
Chemoembolization for Hepatocellular Carcinoma
Lencioni, R. A. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.05.004 · Cited by 98
Self-citationShi, M., Lu, L., Fang, W., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs464 · Cited by 82
Cancer mortality in the United Kingdom: projections to the year 2025
Olsen, A. H., Parkin, D. M., & Sasieni, P. D. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604710 · Cited by 81
Britten, C. D., Gomes, A. S., Wainberg, Z. A., Elashoff, D. A., Amado, R. G., Yan, X., Busuttil, R. W., Slamon, D. J., & Finn, R. S. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-16 · Cited by 48
Hepatocellular carcinoma – Authors' reply
Forner, A., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61286-0 · Cited by 28
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationVillanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Metadata
- Authors
- Lencioni, R., de Baere, T., Soulen, M. C., Rilling, W. S., & Geschwind, J. H.
- Venue
- Hepatology
- Published
- 2016-03-07
- Volume
- 64
- Issue
- 1
- Pages
- 106-116
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2236150109
- Cited by
- 732
- References
- 37
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.